The Triple Agonist
How a single peptide targeting three receptors became the most effective obesity drug in clinical trials
The Next Frontier in Obesity Medicine
In 2023, a clinical trial published in the New England Journal of Medicine reported something unprecedented: a single injectable peptide that helped participants lose approximately 24% of their body weight in 48 weeks. That peptide is retatrutide (LY3437943), and it works by simultaneously activating three hormone receptors that no previous drug had ever targeted together.
Developed by Eli Lilly, retatrutide represents the evolution from semaglutide (one receptor) to tirzepatide (two receptors) to something entirely new: a triple agonist that harnesses GIP, GLP-1, and glucagon signaling at once. This is its story.
The Obesity Crisis
Obesity affects over 650 million adults worldwide and is a leading driver of Type 2 diabetes, cardiovascular disease, fatty liver disease, and multiple cancers. For decades, the only reliable treatment was bariatric surgery.
The arrival of GLP-1 receptor agonists changed everything. Semaglutide (Wegovy) demonstrated ~15% mean body weight loss in the STEP trials, and tirzepatide (Zepbound) pushed that to ~22% in SURMOUNT-1. But even these breakthroughs leave a significant gap -- bariatric surgery achieves 25-35% sustained weight loss, suggesting there was still room for pharmaceutical improvement.
The question was: could a drug match surgery-level efficacy? Eli Lilly's answer was to add a third target.
From Mono to Triple
The incretin drug revolution happened in three waves, each adding a new receptor target and delivering more weight loss.
wave 1 -- GLP-1 agonists (2014-2021): liraglutide (Saxenda, ~8% loss) and semaglutide (Wegovy, ~15% loss) proved that targeting the GLP-1 receptor could suppress appetite, delay gastric emptying, and improve insulin secretion. but they only activated one of the three relevant pathways.
wave 2 -- dual GIP/GLP-1 agonists (2022): tirzepatide (Mounjaro/Zepbound) added GIP receptor agonism. the SURMOUNT-1 trial showed ~22.5% weight loss at the highest dose -- a significant jump over semaglutide. the GIP component added benefits in fat metabolism and energy expenditure.
wave 3 -- triple GIP/GLP-1/glucagon agonists (2023+): retatrutide adds glucagon receptor agonism. the glucagon component drives thermogenesis (heat production from fat burning) and hepatic fat mobilization. the Phase 2 trial showed ~24.2% weight loss at 48 weeks -- approaching bariatric surgery territory.
How It Works
Retatrutide is a single 39-amino-acid peptide engineered to bind and activate three distinct receptors simultaneously.
each receptor contributes something different to weight loss:
GIP receptor: glucose-dependent insulinotropic polypeptide receptor. involved in fat metabolism, energy expenditure, and beta-cell function. this is the component shared with tirzepatide.
GLP-1 receptor: glucagon-like peptide-1 receptor. suppresses appetite via the hypothalamus, delays gastric emptying, and stimulates glucose-dependent insulin secretion. this is the component shared with semaglutide.
glucagon receptor: the key differentiator. activates thermogenesis (increased energy expenditure through heat production), mobilizes fat from the liver, and promotes lipid oxidation. historically avoided because glucagon raises blood sugar -- but the simultaneous GLP-1 agonism counterbalances this effect.
The Headline Numbers
The Phase 2 trial results, published in the New England Journal of Medicine in June 2023, made retatrutide the most effective obesity drug ever tested.
Jastreboff et al. randomized 338 adults with obesity (BMI >= 30, or >= 27 with comorbidities) to receive weekly subcutaneous injections of retatrutide at various doses or placebo for 48 weeks. the results were dose-dependent:
at 1 mg: ~8.7% body weight loss. at 4 mg (two escalation regimens): ~17.1-17.5%. at 8 mg: ~22.8%. at 12 mg: ~24.2%. placebo: ~2.1%. every dose tier exceeded semaglutide's performance, and the highest doses approached bariatric surgery levels.
notably, weight loss curves at 48 weeks had not yet plateaued for the higher doses, suggesting that longer treatment could produce even greater reductions. this is now being tested in the Phase 3 TRIUMPH program.
What's Ahead
Retatrutide is currently in Phase 3 trials under the TRIUMPH program, with results expected to shape the next era of obesity treatment.
the TRIUMPH program includes three major trials: TRIUMPH-1 (obesity without diabetes), TRIUMPH-2 (Type 2 diabetes), and TRIUMPH-3 (metabolic dysfunction-associated steatotic liver disease, formerly NAFLD/NASH). if successful, retatrutide could become the first drug approved for all three conditions.
in the units ahead, you'll learn the molecular architecture behind triple agonism, how each of the three receptor pathways contributes to weight loss, the complete clinical evidence, safety considerations, practical dosing guidance, and how retatrutide compares to every other drug in the obesity landscape. each claim is traced back to its primary research source.
Knowledge Check
Test what you've learned about retatrutide and the triple agonist concept.
Practice Exercises
Reinforce your understanding with interactive exercises.